

CUTIS 1986 INDEX

Volume 37, January-June

Volume 38, July-December

SUBJECT INDEX

A Helpful Aid for Pill Swallowing: The Pop-Bottle Method. *Fowler*. 37: 461 (June)

Accelerated Thyroid Function, Cutaneous Consequences of. *Mullin/Eastern*. 37: 109 (Feb)

Acne, Chap Stick®. *Shelley/Shelley*. 37: 459 (June)

Acneiform Secondary Syphilis, Pustular. *Lambert et al.* 37: 69 (Jan)

Acquired Ichthyosis in a Patient with Adenocarcinoma of the Breast. *Polisky/Bronson*. 38: 359 (Dec)

Amyloidosis, Macular: Treatment with Ultraviolet B. *Hudson*. 38: 61 (July)

Anaphylactoid Purpura, The Koebner Phenomenon in. *Green/Natarajan*. 38: 56 (July)

Angioedema, Aquagenic. *Parks/Camisa*. 37: 465 (June)

Annular Erythema, Reactive, After Intramuscular Vitamin K. *Kay/Duvic*. 37: 445 (June)

Aquagenic Angioedema. *Parks/Camisa*. 37: 465 (June)

Bazex Syndrome: Paraneoplastic Acrokeratosis. *Boudoures/Camisa*. 37: 449 (June)

Black Tongue Secondary to Methyldopa Therapy. *Brody/Cohen*. 38: 187 (Sept)

Bullous Skin Lesion in Familial Mediterranean Fever. *Ronnen et al.* 37: 290 (April)

Cat Scratch Disease Associated with Erythema Nodosum. *Sundaresh et al.* 38: 317 (Nov)

Cephradine, Pustular Eruption Following Administration of. *Kalb/Grossman*. 38: 58 (July)

Chap Stick® Acne. *Shelley/Shelley*. 37: 459 (June)

Cheilitis, Clarinettist's. *Friedman/Connolly*. 38: 183 (Sept)

Chronic Leg Ulcers and Klinefelter's Syndrome. *Downham/Mitek*. 38: 110 (Aug)

Clarinettist's Cheilitis. *Friedman/Connolly*. 38: 183 (Sept)

Congenital Melanocytosis with Myelomeningocele and Hydrocephalus. *Schwartz et al.* 37: 37 (Jan)

Cryptogenic Drug Eruption Resulting from Cephalosporin Lavage. *Szylit/Grossman*. 37: 390 (May)

Cutaneous Consequences of Accelerated Thyroid Function. *Mullin/Eastern*. 37: 109 (Feb)

Cutaneous Erythrophagocytosis, Malignant Histiocytosis Presenting with Vasculitis and. *Reed et al.* 38: 63 (July)

Cutaneous Nerve Components, Electron Microscopy of *Mycobacterium Leprae* in. *Imaeda/Imaeda*. 37: 59 (Jan)

Cutaneous Ulcers Caused by *Leishmania brasiliensis*, Failure of Oral Ketoconazole to Cure. *Dan et al.* 38: 198 (Sept)

Dermatitis Herpetiformis and Vitiligo. *Hogan/Lane*. 38: 195 (Sept)

Dermatitis, Poison Ivy. *Baer*. 37: 434 (June)

Dermatofibromas, Multiple, and Systemic Lupus Erythematosus. *Lin et al.* 37: 45 (Jan)

Dermatologic Features of the Fat Embolism Syndrome. *Kaplan et al.* 38: 52 (July)

Detailed, Controlled, and Documented Self-Experimentation in Dermatology. *Goldman*. 37: 196 (March)

Diagnostic Criteria for Sweet's Syndrome. *Su/Liu* 37: 167 (March)

Discrete Palmar and Plantar Symptoms in Children with Dermatitis Herpetiformis Duhring. *Karpati et al.* 37: 184 (March)

Dressings for Dermabrasion: Occlusive Dressings and Wound Healing. *Pinski*. 37: 471 (June)

Earlobe Keloids, Recurrent, Treatment of. *Rauscher/Kolmer*. 37: 67 (Jan)

Electron Microscopy of *Mycobacterium Leprae* in Cutaneous Nerve Components. *Imaeda/Imaeda*. 37: 59 (Jan)

Elephantoid Lymphedema, Nodular. *Richards*. 38: 67 (July)

Epidermal Nevus Misinterpreted as Child Abuse. *Sekula et al.* 37: 276 (April)

Erythema Dyschromicum Perstans. *Lambert et al.* 37: 42 (Jan)

Erythema Nodosum, Cat Scratch Disease Associated with. *Sundaresh et al.* 38: 317 (Nov)

Erythematous Plaque Variant of Transient Acantholytic Dermatosis. *Horiuchi et al.* 38: 48 (July)

Erythroderma with Fulminant Hepatitis: A Possible Association. *Schwartz et al.* 37: 56 (Jan)

Exacerbation of Psoriasis by Ibuprofen. *Ben-Chetrit/Rubinow*. 38: 45 (July)

Exploratory Nail Plate Removal as a Diagnostic Aid in Painful Subungual Tumors: Glomus Tumor, Neurofibroma, and Squamous Cell Carcinoma. *Shelley/Shelley*. 38: 310 (Nov)

Failure of Oral Ketoconazole to Cure Cutaneous Ulcers Caused by *Leishmania brasiliensis*. *Dan et al.* 38: 198 (Sept)

Familial Lichen Planus. *Lin et al.* 37: 135 (Feb)

Familial Mediterranean Fever, Bullous Skin Lesion in. *Ronnen et al.* 37: 290 (April)

Familial Netherton's Disease. *Kassis et al.* 38: 175 (Sept)

Fixed Drug Eruption to Sulindac. *Bruce/Odom*. 38: 323 (Nov)

CUTIS 1986 INDEX

Volume 37, January-June

Volume 38, July-December

SUBJECT INDEX

A Helpful Aid for Pill Swallowing: The Pop-Bottle Method. *Fowler*. 37: 461 (June)

Accelerated Thyroid Function, Cutaneous Consequences of. *Mullin/Eastern*. 37: 109 (Feb)

Acne, Chap Stick®. *Shelley/Shelley*. 37: 459 (June)

Acneiform Secondary Syphilis, Pustular. *Lambert et al.* 37: 69 (Jan)

Acquired Ichthyosis in a Patient with Adenocarcinoma of the Breast. *Polisky/Bronson*. 38: 359 (Dec)

Amyloidosis, Macular: Treatment with Ultraviolet B. *Hudson*. 38: 61 (July)

Anaphylactoid Purpura, The Koebner Phenomenon in. *Green/Natarajan*. 38: 56 (July)

Angioedema, Aquagenic. *Parks/Camisa*. 37: 465 (June)

Annular Erythema, Reactive, After Intramuscular Vitamin K. *Kay/Duvic*. 37: 445 (June)

Aquagenic Angioedema. *Parks/Camisa*. 37: 465 (June)

Bazex Syndrome: Paraneoplastic Acrokeratosis. *Boudoures/Camisa*. 37: 449 (June)

Black Tongue Secondary to Methyldopa Therapy. *Brody/Cohen*. 38: 187 (Sept)

Bullous Skin Lesion in Familial Mediterranean Fever. *Ronnen et al.* 37: 290 (April)

Cat Scratch Disease Associated with Erythema Nodosum. *Sundaresh et al.* 38: 317 (Nov)

Cephradine, Pustular Eruption Following Administration of. *Kalb/Grossman*. 38: 58 (July)

Chap Stick® Acne. *Shelley/Shelley*. 37: 459 (June)

Cheilitis, Clarinettist's. *Friedman/Connolly*. 38: 183 (Sept)

Chronic Leg Ulcers and Klinefelter's Syndrome. *Downham/Mitek*. 38: 110 (Aug)

Clarinettist's Cheilitis. *Friedman/Connolly*. 38: 183 (Sept)

Congenital Melanocytosis with Myelomeningocele and Hydrocephalus. *Schwartz et al.* 37: 37 (Jan)

Cryptogenic Drug Eruption Resulting from Cephalosporin Lavage. *Szylit/Grossman*. 37: 390 (May)

Cutaneous Consequences of Accelerated Thyroid Function. *Mullin/Eastern*. 37: 109 (Feb)

Cutaneous Erythrophagocytosis, Malignant Histiocytosis Presenting with Vasculitis and. *Reed et al.* 38: 63 (July)

Cutaneous Nerve Components, Electron Microscopy of *Mycobacterium Leprae* in. *Imaeda/Imaeda*. 37: 59 (Jan)

Cutaneous Ulcers Caused by *Leishmania brasiliensis*, Failure of Oral Ketoconazole to Cure. *Dan et al.* 38: 198 (Sept)

Dermatitis Herpetiformis and Vitiligo. *Hogan/Lane*. 38: 195 (Sept)

Dermatitis, Poison Ivy. *Baer*. 37: 434 (June)

Dermatofibromas, Multiple, and Systemic Lupus Erythematosus. *Lin et al.* 37: 45 (Jan)

Dermatologic Features of the Fat Embolism Syndrome. *Kaplan et al.* 38: 52 (July)

Detailed, Controlled, and Documented Self-Experimentation in Dermatology. *Goldman*. 37: 196 (March)

Diagnostic Criteria for Sweet's Syndrome. *Su/Liu* 37: 167 (March)

Discrete Palmar and Plantar Symptoms in Children with Dermatitis Herpetiformis Duhring. *Karpati et al.* 37: 184 (March)

Dressings for Dermabrasion: Occlusive Dressings and Wound Healing. *Pinski*. 37: 471 (June)

Earlobe Keloids, Recurrent, Treatment of. *Rauscher/Kolmer*. 37: 67 (Jan)

Electron Microscopy of *Mycobacterium Leprae* in Cutaneous Nerve Components. *Imaeda/Imaeda*. 37: 59 (Jan)

Elephantoid Lymphedema, Nodular. *Richards*. 38: 67 (July)

Epidermal Nevus Misinterpreted as Child Abuse. *Sekula et al.* 37: 276 (April)

Erythema Dyschromicum Perstans. *Lambert et al.* 37: 42 (Jan)

Erythema Nodosum, Cat Scratch Disease Associated with. *Sundaresh et al.* 38: 317 (Nov)

Erythematous Plaque Variant of Transient Acantholytic Dermatosis. *Horiuchi et al.* 38: 48 (July)

Erythroderma with Fulminant Hepatitis: A Possible Association. *Schwartz et al.* 37: 56 (Jan)

Exacerbation of Psoriasis by Ibuprofen. *Ben-Chetrit/Rubinow*. 38: 45 (July)

Exploratory Nail Plate Removal as a Diagnostic Aid in Painful Subungual Tumors: Glomus Tumor, Neurofibroma, and Squamous Cell Carcinoma. *Shelley/Shelley*. 38: 310 (Nov)

Failure of Oral Ketoconazole to Cure Cutaneous Ulcers Caused by *Leishmania brasiliensis*. *Dan et al.* 38: 198 (Sept)

Familial Lichen Planus. *Lin et al.* 37: 135 (Feb)

Familial Mediterranean Fever, Bullous Skin Lesion in. *Ronnen et al.* 37: 290 (April)

Familial Netherton's Disease. *Kassis et al.* 38: 175 (Sept)

Fixed Drug Eruption to Sulindac. *Bruce/Odom*. 38: 323 (Nov)

Frostbite Desquamation of the Soles as the Presenting Sign of Leukemia. *Shelley/Shelley*. 38: 259 (Oct)

Granuloma Annulare, Inflammatory. *Burnett et al.* 37: 267 (April)

Graves' Disease, Tinea Corporis Overlying the Thyroid Gland After Radioiodine (¹³¹I) Treatment of. *Moreno et al.* 37: 271 (April)

Herpes Simplex, Treatment of, with Topical Zinc. *Finnerty*. 37: 130 (Feb)

Hepatitis, Fulminant, and Erythroderma: A Possible Association. *Schwartz et al.* 37: 56 (Jan)

Hyperbaric Oxygen Treatment of Toxic Epidermal Necrolysis. *Ruocco et al.* 38: 267 (Oct)

Ibuprofen, Exacerbation of Psoriasis by. *Ben-Chetrit/Rubinow*. 38: 45 (July)

Inflammatory Granuloma Annulare. *Burnett et al.* 37: 267 (April)

Interdigital Angioleiomyoma. *Brenner/Rabinowitz*. 37: 350 (May)

Intraepidermal Epithelioma of Jadassohn. *Sampson et al.* 37: 339 (May)

Isotretinoin in the Treatment of Steatocystoma Multiplex: A Possible Adverse Reaction. *Rosen/Brodkin*. 37: 115 (Feb)

Ivy, Poison, Dermatitis. *Baer*. 37: 434 (June)

Keloids, Earlobe, Treatment of. *Rauscher/Kolmer*. 37: 67 (Jan)

Klinefelter's Syndrome, Chronic Leg Ulcers and. *Downham/Mitek*. 38: 110 (Aug)

Koebner Phenomenon in Anaphylactoid Purpura, The. *Green/Natarajan*. 38: 56 (July)

Lamellar Ichthyosis with Episodic Psoriasisiform Reaction Pattern. *Kahn et al.* 37: 162 (March)

Lamellar Ichthyosis, Vacuolar Myelinopathy of the Brain and. *Sadick/Sternberg*. 38: 29 (July)

Lasers in Private Dermatologic Practice. *Eastern*. 37: 293 (April)

Leishmania brasiliensis, Failure of Oral Ketoconazole to Cure Cutaneous Ulcers Caused by. *Dan et al.* 38: 198 (Sept)

Leukemids, Papular. *Marx et al.* 37: 201 (March)

Lichen Planus, Familial. *Lin et al.* 37: 135 (Feb)

Linear IgA Bullous Disease in a Patient with Transitional Cell Carcinoma of the Bladder. *Sekula et al.* 38: 354 (Dec)

Lips: Anatomy and Differential Diagnosis. *Zugerman*. 38: 116 (Aug)

Localized Cicatricial Pemphigoid (Brunsting-Perry Syndrome). *Gibson et al.* 38: 252 (Oct)

Lupus Erythematosus, Systemic, A Unique Association with Pemphigus Erythematosus. *Ngo et al.* 38: 160 (Sept)

Lymphedema, Nodular Elephantoid. *Richards*. 38: 67 (July)

Lymphedema Tarda. *Majeski*. 38: 105 (Aug)

Macular Amyloidosis: Treatment with Ultraviolet B. *Hudson*. 38: 61 (July)

Malignant Histiocytosis Presenting with Vasculitis and Cutaneous Erythrophagocytosis. *Reed et al.* 38: 63 (July)

Mask Phenomenon: Postemesis Facial Purpura. *Alcalay et al.* 38: 28 (July)

Melanocytosis, Congenital, with Myelomeningocele and Hydrocephalus. *Schwartz et al.* 37: 37 (Jan)

Methyldopa, Black Tongue Secondary to. *Brody/Cohen*. 38: 187 (Sept)

Miliaria Crystallina Occurring in a Patient Treated with Isotretinoin. *Gupta et al.* 38: 275 (Oct)

Multiple Dermatofibromas and Systemic Lupus Erythematosus. *Lin et al.* 37: 45 (Jan)

Nail Plate Removal, Exploratory, as a Diagnostic Aid in Painful Subungual Tumors: Glomus Tumor, Neurofibroma, and Squamous Cell Carcinoma. *Shelley/Shelley*. 38: 310 (Nov)

Naproxen Photosensitization Demonstrated by Challenge. *Shelley et al.* 38: 169 (Sept)

Netherton's Disease, Familial. *Kassis et al.* 38: 175 (Sept)

Nodular Elephantoid Lymphedema. *Richards*. 38: 67 (July)

Occlusive Dressings and Wound Healing, Dressings for Dermabrasion. *Pinski*. 37: 471 (June)

Papular Leukemids. *Marx et al.* 37: 201 (March)

Paraneoplastic Acrokeratosis: Bazex Syndrome. *Boudoulas/Camisa*. 37: 449 (June)

Pemphigus Erythematosus: A Unique Association with Systemic Lupus Erythematosus. *Ngo et al.* 38: 160 (Sept)

Piezosurgery: A Conservative Approach to Encapsulated Skin Lesions. *Shelley/Shelley*. 38: 123 (Aug)

Pigmentary Demarcation Lines During Pregnancy. *Vázquez et al.* 38: 263 (Oct)

Pill Swallowing: The Pop-Bottle Method, A Helpful Aid for. *Fowler*. 37: 461 (June)

Pityriasis Rotunda. *Walsman*. 38: 247 (Oct)

Poison Ivy Dermatitis. *Baer*. 37: 434 (June)

Polyarthritis: Pustular Dermatoses with. *Lin et al.* 37: 123 (Feb)

Prayer Nodules in Moslem Men. *Kahana et al.* 38: 281 (Oct)

Psoriasis, Exacerbation of, by Ibuprofen. *Ben-Chetrit/Rubinow*. 38: 45 (July)

Psoriasis Vulgaris of Labium Majus. *Weinrauch/Katz*. 38: 333 (Nov)

Purpura, Anaphylactoid, the Koebner Phenomenon in. *Green/Natarajan*. 38: 56 (July)

Purpura, Postemesis Facial, Mask Phenomenon. *Alcalay et al.* 38: 28 (July)

Pustular Acneiform Secondary Syphilis. *Lambert et al.* 37: 69 (Jan)

Pustular Dermatoses with Polyarthritis, Subcorneal. *Lin et al.* 37: 123 (Feb)

(CONTINUED ON PAGE 384)



FOR CLASS 1 POTENCY[®]
DIPROLENE[®]
brand of betamethasone dipropionate
Ointment, USP, 0.05%
IN ACTIBASE[®]

(potency expressed as betamethasone)

For Dermatologic Use Only — Not for Ophthalmic Use

Summary of Prescribing Information:

INDICATIONS AND USAGE: DIPROLENE Ointment is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS: DIPROLENE Ointment is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.

PRECAUTIONS General Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent corticosteroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. [See **DOSE AND ADMINISTRATION** section.]

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. [See **PRECAUTIONS — Pediatric Use**.] If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Carcogenesis, Mutagenesis, and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topically applied corticosteroids.

Studies to determine mutagenicity with prednisolone have revealed negative results.

Pregnancy Category C: Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies of the teratogenic effects of topically applied corticosteroids in pregnant women. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are prescribed for a nursing woman.

Pediatric Use: Use of DIPROLENE Ointment in children under 12 years is not recommended.

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

ADVERSE REACTIONS: The local adverse reactions that were reported with DIPROLENE Ointment during clinical studies are as follows: folliculitis, 2 per 500 patients; erythema, 2 per 500 patients; pruritis, 1 per 500 patients; vesication, 1 per 500 patients.

The following local adverse reactions are reported infrequently when topical corticosteroids are used as recommended. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, periorificial dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, milia.

OVERDOSAGE: Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. [See **PRECAUTIONS**.]

DOSE AND ADMINISTRATION: Apply a thin film of DIPROLENE Ointment to the affected skin area, twice daily, once in the morning and once at night. Amounts greater than 45 g per week should not be used.

DIPROLENE Ointment is **not to be used with occlusive dressings.** HOW SUPPLIED: DIPROLENE Ointment 0.05% is supplied in 15-(NDC 0085-057-02), and 45-gram (NDC 0085-057-03) tubes; boxes of one.

Store between 2° and 30° C (36° and 86°F).

For more complete details, consult package insert or Schering literature available from your Schering Representative or Professional Services Department, Schering Corporation, Kenilworth, New Jersey 07033.

Rev. B/84
12923414

Reference: 1. Cornell RC, Stoughton RB: Topical corticosteroids, in Roenigk H, Maibach H [eds]: *Psoriasis*. New York, Marcel Dekker, 1985, pp 337-362.



Schering Corporation
Kenilworth, NJ 07033

DL-A132/13432902

(CONTINUED FROM PAGE 381)

Pustular Eruption Following Administration of Cephadrine. Kalb/Grossman. 38: 58 (July)

Reactive Annular Erythema After Intramuscular Vitamin K. Kay/Duvic. 37: 445 (June)

Recurrent Cutaneous Leishmaniasis: Successful Treatment with Sodium Antimony Gluconate. Aram/El-On. 37: 177 (March)

Recurrent Earlobe Keloids, Treatment of. Rauscher/Kolmer. 37: 67 (Jan)

Response of Varicella Zoster Virus and Herpes Zoster to Silver Sulfadiazine. Montes et al. 38: 363 (Dec)

Steatocystoma Multiplex: Isotretinoin in the Treatment of: A Possible Adverse Reaction. Rosen/Brodkin. 37: 115 (Feb)

Subcorneal Pustular Dermatosis with Polyarthritis. Lin et al. 37: 123 (Feb)

Sulfadiazine, Silver, Response of Varicella Zoster Virus and Herpes Zoster to. Montes et al. 38: 363 (Dec)

Sulindac, Fixed Drug Eruption to. Bruce/Odom. 38: 323 (Nov)

Surgical Procedures for the Treatment of Baldness. Stough et al. 37: 362 (May)

Sweet's Syndrome, Diagnostic Criteria for. Su/Liu. 37: 167 (March)

Tinea Corporis Overlying the Thyroid Gland After Radioiodine (¹³¹I) Treatment of Graves' Disease. Moreno et al. 37: 271 (April)

Topical Zinc in the Treatment of Herpes Simplex. Finnerty. 37: 130 (Feb)

Toxic Epidermal Necrolysis, Hyperbaric Oxygen Treatment of. Ruocco et al. 38: 267 (Oct)

Transient Acantholytic Dermatoses, Erythematous Plaque Variant of. Horiuchi et al. 38: 48 (July)

Treatment of Recurrent Earlobe Keloids. Rauscher/Kolmer. 37: 67 (Jan)

Treatment of Steatocystoma Multiplex, Isotretinoin in the: A Possible Adverse Reaction. Rosen/Brodkin. 37: 115 (Feb)

Use of Colchicine in Behcet's Syndrome. Sander/Randle. 37: 344 (May)

Vacuolar Myelinopathy of the Brain and Lamellar Ichthyosis. Sadick/Sternberg. 38: 29 (July)

Varicella Zoster Virus and Herpes Zoster, Response of, to Silver Sulfadiazine. Montes et al. 38: 363 (Dec)

Vasculitis and Cutaneous Erythrophagocytosis, Malignant Histiocytosis Presenting with. Reed et al. 38: 63 (July)

Vitiligo, Dermatitis Herpetiformis and. Hogan/Lane. 38: 195 (Sept)

Xeroderma Pigmentosum in Qatar. Fathy/Khafagy. 37: 377 (May)

Yellow Nail Syndrome. Gupta et al. 37: 371 (May)

AUTHOR INDEX

Alcalay J, Ingber A, Sandbank M: Mask Phenomenon: Postemesis Facial Purpura. 38: 28 (July)

Altman A: See Kahn

Aram H, El-On J: Recurrent Cutaneous Leishmaniasis: Successful Treatment with Sodium Antimony Gluconate. 37: 177 (March)

Baer RL: Poison Ivy Dermatitis. 37: 434 (June)

Bagley MP: See Lambert

Bean SF: See Gibson

Bean SF: See Sekula

Behm FG: See Reed

Ben-Chetrit E, Rubinow A: Exacerbation of Psoriasis by Ibuprofen. 38: 45 (July)

Billick RC: See Lin AN

Bimonte D: See Ruocco

Boudoulas O, Camisa C: Paraneoplastic Acrokeratosis: Bazex Syndrome. 37: 449 (June)

Brenner MA, Rabinowitz AD: Interdigital Angioleiomyoma. 37: 350 (May)

Brodkin RH: See Rosen

Brody HJ, Cohen M: Black Tongue Secondary to Methyldopa Therapy. 38: 187 (Sept)

Bronson DM: See Polisky

Bruce DR, Odom RB: Fixed Drug Eruption to Sulindac. 38: 323 (Nov)

Burnett JW, Wood C, Sina B, Dilaimy M: Inflammatory Granuloma Annulare. 37: 267 (April)

Camisa C: See Boudoulas

Camisa C: See Parks

Camisa C: See Sundaresh

Carvallo E: See Sundaresh

Cohen-Addad N: See Schwartz

Cohen M: See Brody

Cohen M: See Kahana

Cohen PJ: See Schwartz

Connolly SM: See Friedman

Crooks LA: See Moreno

Dahl-Christensen J: See Kassis

Dan M, Verner E, El-On J, Zuckerman F, Michaeli D: Failure of Oral Ketoconazole to Cure Cutaneous Ulcers Caused by *Leishmania brasiliensis*. 38: 198 (Sept)

Davies GM: See Gupta

Dilaimy M: See Burnett

Downham TF II, Mitek FV: Chronic Leg Ulcers and Klinefelter's Syndrome. 38: 110 (Aug)

Duffy JO: See Sekula

Duvic M: See Kay

Eastern JS: Lasers in Private Dermatologic Practice. 37: 293 (April)

Eastern JS: See Mullin

Ellis CN: See Gupta

El-On J: See Aram

El-On J: See Dan

Elpern DJ: See Shelley

Fathy S, Khafagy H: Xeroderma Pigmentosum in Qatar. 37: 377 (May)

Finnerty E: Topical Zinc in the Treatment of Herpes Simplex. 37: 130 (Feb)

Florio M: See Ruocco

Fowler JF Jr: A Helpful Aid for Pill Swallowing: The Pop-Bottle Method. 37: 461 (June)

Fox BJ: See Moreno

Fox CL Jr: See Montes

Freilich IW: See Stough

Fretzin D: See Ngo

Friedman SJ, Connolly SM: Clarinettist's Cheilitis. 38: 183 (Sept)

Garrett A: See Reed

Gibson V, Tschen JA, Bean SF: Localized Cicatricial Pemphigoid (Brunsting-Perry Syndrome). 38: 252 (Oct)

Goldman L: Detailed, Controlled, and Documented Self-Experimentation in Dermatology. 37: 196 (March)

Grant JN: See Kaplan

Green ST, Natarajan S: The Koebner Phenomenon in Anaphylactoid Purpura. 38: 56 (July)

Grossman ME: See Kalb

Grossman ME: See Szylit

Gupta AK, Ellis CN, Madison KC, Voorhees JJ: Miliaria Crystallina Occurring in a Patient Treated with Isotretinoin. 38: 275 (Oct)

Gupta AK, Davies GM, Haberman HF: Yellow Nail Syndrome. 37: 371 (May)

Haberman HF: See Gupta

Hamilton GB: See Lambert

Hartshorne MF: See Moreno

Hogan DJ, Lane P: Dermatitis Herpetiformis and Vitiligo. 38: 195 (Sept)

Horiuchi Y, Umezawa A, Kamimura K: Erythematous Plaque Variant of Transient Acantholytic Dermatosis. 38: 48 (July)

Hudson LD: Macular Amyloidosis: Treatment with Ultraviolet B. 38: 61 (July)

Hutchinson E: See Kahn

Ibañez MI: See Vázquez

Imaeda H: See Imaeda T

Imaeda T, Imaeda H: Electron Microscopy of *Mycobacterium leprae* in Cutaneous Nerve Components. 37: 59 (Jan)

Indianer L: See Sampson

Ingber A: See Alcalay

Kahana M, Cohen M, Ronnen M, Levy A, Schewach-Millet M: Prayer Nodules in Moslem Men. 38: 281 (Oct)

Kahn D, Altman J, Hutchinson E: Lamellar Ichthyosis with Episodic Psoriasisiform Reaction Pattern. 37: 162 (March)

Kalb RE, Grossman ME: Pustular Eruption Following Administration of Cephradine. 38: 58 (July)

Kamimura K: See Horiuchi

Kaplan RP, Grant JN, Kaufman AJ: Dermatologic Features of the Fat Embolism Syndrome. 38: 52 (July)

Karpati S, Torok E, Kosnai I: Discrete Palmar and

Plantar Symptoms in Children with Dermatitis Herpetiformis Duhring. 37: 184 (March)

Kassis V, Nielsen JM, Klem-Thomsen H, Dahl-Christensen J, Wadskov S: Familial Netherton's Disease. 38: 175 (Sept)

Katz M: See Weinrauch

Kaufman AJ: See Kaplan

Kay MH, Duvic M: Reactive Annular Erythema After Intramuscular Vitamin K. 37: 445 (June)

Kelley AP: See Sampson

Khafagy H: See Fathy

Khan Y: See Lambert

Klem-Thomsen H: See Kassis

Kolmer WL: See Rauscher

Kosnai I: See Karpati

Krey PR: See Lin

Lambert MW: See Schwartz

Lambert WC: See Lin

Lambert WC: See Schwartz

Lambert WC, Bagley MP, Khan Y, Schwartz RA: Pustular Acneiform Secondary Syphilis. 37: 69 (Jan)

Lambert WC, Schwartz RA, Hamilton GB: Erythema Dyschromicum Perstans. 37: 42 (Jan)

Landsman L: See Lin

Lane P: See Hogan

Leevy CM: See Schwartz

Levy A: See Kahana

Lin AN, Srolovitz H, Billick RC: Familial Lichen Planus. 37: 135 (Feb)

Lin RY, Landsman L, Krey PR, Lambert WC: Multiple Dermatofibromas and Systemic Lupus Erythematosus. 37: 45 (Jan)

Lin RY, Schwartz RA, Lambert WC: Subcorneal Pustular Dermatosis with Polyarthritis. 37: 123 (Feb)

Littman B: See Reed

Liu HNH: See Su

Luongo C: See Ruocco

Madison KC: See Gupta

Madjar DD Jr: See Sundaresan

Majeski J: Lymphedema Tarda. 38: 105 (Aug)

Marx LH, Woodman RC, Pineo GF: Papular Leukemias. 37: 201 (March)

Mendoza F: See Stough

Michaeli D: See Dan

Mitek FV: See Downham

Montes LF, Muchnik G, Fox CL Jr: Response of Varicella Zoster Virus and Herpes Zoster to Silver Sulfadiazine. 38: 363 (Dec)

Moreno AJ, Hartshorne MF, Yedinak MA, Crooks LA, Fox BJ: Tinea Corporis Overlying the Thyroid Gland After Radioiodine (¹³¹I) Treatment of Graves' Disease. 37: 271 (April)

Muchnik G: See Montes

Mullin GE, Eastern JS: Cutaneous Consequences of Accelerated Thyroid Function. 37: 109 (Feb)

Natarajan S: See Green

Ngo AW, Straka C, Fretzin D: Pemphigus Erythematous: A Unique Association with Systemic Lupus Erythematosus. 38: 160 (Sept)

Nielsen JM: See Kassis

Odom RB: See Bruce

Parks A, Camisa C: Aquagenic Angioedema. 37: 465 (June)

Patterson JW: See Reed

Pineo GF: See Marx

Pinski JB: Dressings for Dermabrasion: Occlusive Dressings and Wound Healing. 37: 471 (June)

Polisky RB, Bronson DM: Acquired Ichthyosis in a Patient with Adenocarcinoma of the Breast. 38: 359 (Dec)

Rabinowitz AD: See Brenner

Randle HW: See Sander

Rauscher GE, Kolmer WL: Treatment of Recurrent Earlobe Keloids. 37: 67 (Jan)

Reed WW, Patterson JW, Behm FG, Littman B, Garrett A: Malignant Histiocytosis Presenting with Vasculitis and Cutaneous Erythrophagocytosis. 38: 63 (July)

Richards RN: Nodular Elephantoid Lymphedema. 38: 67 (July)

Ronnen M: See Kahana

Ronnen M, Suster SM, Schewach-Millet M: Bullous Skin Lesion in Familial Mediterranean Fever. 37: 290 (April)

Rosen BL, Brodkin RH: Isotretinoin in the Treatment of Steatocystoma Multiplex: A Possible Adverse Reaction. 37: 115 (Feb)

Robinow A: See Ben-Chetrit

Ruocco V, Bimonte D, Luongo C, Florio M: Hyperbaric Oxygen Treatment of Toxic Epidermal Necrolysis. 38: 267 (Oct)

Sadick N, Sternberg PE: Vacuolar Myelinopathy of the Brain and Lamellar Ichthyosis. 38: 29 (July)

Sampson DD, Kelley AP, Indianer L: Intraepidermal Epithelioma of Jadassohn. 37: 339 (May)

Sánchez JL: See Vázquez

Sandbank M: See Alcalay

Sander HM, Randle HW: Use of Colchicine in Behcet's Syndrome. 37: 344 (May)

Schewach-Millet: See Kahana

Schwartz RA: See Lambert

Schwartz RA: See Lin

Schwartz RA, Cohen-Addad N, Lambert MW, Lambert WC: Congenital Melanocytosis with Myelomeningocele and Hydrocephalus. 37: 37 (Jan)

Schwartz RA, Leevy CM, Cohen PJ, Lambert WC: Erythroderma with Fulminant Hepatitis: A Possible Association. 37: 56 (Jan)

Sekula SA, Tschen JA, Duffy JO: Epidermal Nevus Misinterpreted as Child Abuse. 37: 276 (April)

Sekula SA, Tschen JA, Bean SF, Wolf JE Jr: Linear IgA Bullous Disease in a Patient with Transitional Cell Carcinoma of the Bladder. 38: 354 (Dec)

(CONTINUED ON PAGE 389)

In Acne Cleocin^T_® (clindamycin phosphate)

It can make a difference

Cleocin^T_® Topical Solution
(clindamycin phosphate)

INDICATIONS: CLEOCIN T Topical Solution is indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea, and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS).

CONTRAINDICATIONS: CLEOCIN T is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincosycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.

WARNINGS: Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally. Use of the topical formulation results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. Symptoms can occur after a few days, weeks or months following initiation of clindamycin therapy. They have also been observed to begin up to several weeks after cessation of therapy with clindamycin. Studies indicate a toxin(s) produced by *Clostridium difficile* is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Endoscopic examination may reveal pseudomembranous colitis.

When significant diarrhea occurs, the drug should be discontinued. Large bowel endoscopy should be considered in cases of severe diarrhea.

Antiperistaltic agents such as opiates and Lomotil may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated pseudomembranous colitis produced by *Clostridium difficile*. The usual adult dosage is 500 mg.

Mild cases of colitis may respond to discontinuance of clindamycin. Moderate to severe cases should be managed promptly with fluid, electrolyte, and protein supplementation as indicated. Cholestyramine and colestipol resins have been shown to bind the toxin in vitro. If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug. Systemic corticoids and corticoid retention enemas may help. Other causes of colitis should also be considered.

PRECAUTIONS: CLEOCIN T contains an alcohol base which will cause burning and irritation of the eye. In the event of accidental contact with sensitive surfaces (eye, abraded skin, mucous membranes), bathe with copious amounts of cool tap water. The solution tastes unpleasant.

CLEOCIN T should be prescribed with caution in atopic individuals.

Pregnancy: This drug should be used during pregnancy only if clearly needed.

Nursing Mothers: Nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.

ADVERSE REACTIONS: Skin dryness is the most common adverse reaction. Clindamycin has been associated with severe colitis which may end fatally (see WARNINGS).

Cases of diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported in patients treated with topical clindamycin.

Other effects which have been reported in association with topical formulations include:

Abdominal pain	Gram-negative folliculitis	Sensitization
Contact dermatitis	Irritation	Stinging of the eye
Gastrointestinal disturbances	Oily skin	

DOSAGE AND ADMINISTRATION: Apply a thin film of CLEOCIN T Topical Solution twice daily to affected area.

HOW SUPPLIED: CLEOCIN T Topical Solution containing clindamycin phosphate equivalent to 10 mg clindamycin per milliliter is available in the following sizes:

30 ml applicator bottle	NDC 0009-3116-01
60 ml applicator bottle	NDC 0009-3116-02
16 oz (473 ml) bottle	NDC 0009-3116-04

The applicator is designed so that the solution may be applied directly to the involved skin.

Caution: Federal law prohibits dispensing without prescription. B-2-S

For additional product information, see package insert or consult your Upjohn representative.

CLEOCIN T is a registered trademark of The Upjohn Manufacturing Company.

Upjohn

The Upjohn Company
Kalamazoo, Michigan 49001

January 1985
J-5121

(CONTINUED FROM PAGE 387)

Shelley ED: See Shelley WB

Shelley ED, Shelley WB: Exploratory Nail Plate Removal as a Diagnostic Aid in Painful Subungual Tumors: Glomus Tumor, Neurofibroma, and Squamous Cell Carcinoma. 38: 310 (Nov)

Shelley WB, Shelley ED: Frostbite Desquamation of the Soles as the Presenting Sign of Leukemia. 38: 259 (Oct)

Shelley ED, Shelley WB: Piezosurgery: A Conservative Approach to Encapsulated Skin Lesions. 38: 123 (Aug)

Shelley WB: See Shelley ED

Shelley WB, Shelley ED: Chap Stick[®] Acne. 37: 459 (June)

Shelley WB, Elpern DJ, Shelley ED: Naproxen Photosensitization Demonstrated by Challenge. 38: 169 (Sept)

Sina B: See Burnett

Srolovitz H: See Lin AN

Sternberg PE: See Sadick

Stough DB III, Mendoza F, Freilich IW: Surgical Procedures for the Treatment of Baldness. 37: 362 (May)

Straka C: See Ngo

Su WPD, Liu HNH: Diagnostic Criteria for Sweet's Syndrome. 37: 167 (March)

Sundaresh KV, Madjar DD Jr, Camisa C, Carvallo E: Cat Scratch Disease Associated with Erythema Nodosum. 38: 317 (Nov)

Suster SM: See Ronnen

Szylit J, Grossman ME: Cryptogenic Drug Eruption Resulting from Cephalosporin Lavage. 37: 390 (May)

Torok E: See Karpati

Tschen JA: See Gibson

Tschen JA: See Sekula

Umezawa A: See Horiuchi

Vázquez M, Ibañez MI, Sánchez JL: Pigmentary Demarcation Lines During Pregnancy. 38: 263 (Oct)

Verner E: See Dan

Voorhees JJ: See Gupta

Wadskov S: See Kassis

Waisman M: Pityriasis Rotunda. 38: 247 (Oct)

Weinrauch L, Katz M: Psoriasis Vulgaris of Labium Majus. 38: 333 (Nov)

Wolf JE Jr: See Sekula

Wood C: See Burnett

Woodman RC: See Marx

Yedinak MA: See Moreno

Zuckerman F: See Dan

Zugerman C: The Lips: Anatomy and Differential Diagnosis. 38: 116 (Aug)

Department and Special Feature Index

COSMETOLOGY

(Prepared especially for CUTIS by Allen J. Natow, MD)
Hair Bleach. 37: 28 (Jan)
Aloe Vera, Fiction or Fact. 37: 106 (Feb)
Talc: Need We Beware? 37: 328 (May)
Henna. 38: 21 (July)
Chemical Removal of Hair. 38: 91 (Aug)
Sunscreens. 38: 157 (Sept)
Promotion of Hair Growth. 38: 241 (Oct)

CURRENT CONTACT NEWS

(Prepared especially for CUTIS by A. A. Fisher, MD)
Acne Venenata in Black Skin. 37: 24 (Jan)
Erythema Multiforme-like Eruptions Due to Exotic Woods and Ordinary Plants. 37: 101 (Feb)
Erythema Multiforme-like Eruptions Due to Topical Medications: Part II. 37: 158 (March)
Erythema Multiforme-like Eruptions Due to Topical Miscellaneous Compounds: Part III. 37: 262 (April)
The Safety of Artificial Hip Replacement in Nickel-Sensitive Patients. 37: 333 (May)
Reactions to Acrylic Bone Cement in Orthopedic Surgeons and Patients. 37: 425 (June)
Reactions to Menthol. 38: 17 (July)
Compound ("Synergistic") Allergy to Contactants. 38: 101 (Aug)
"Terminal" Dermatitis Due to Computers (Visual Display Units). 38: 153 (Sept)
Allergic Dermatitis from Acupuncture Needles. 38: 226 (Oct)
Contact Urticaria Due to Cornstarch Surgical Glove Powder. 38: 307 (Nov)
Dermatitis Due to Swim Gear. 38: 353 (Dec)

DISEASES OF THE NAILS

(Prepared especially for CUTIS by Richard K. Scher, MD)
Digital Myxoid Cysts: A Review. *Sonnex*. 37: 89 (Feb)
Surgical Treatment of Ingrowing Toenails. *Haneke*. 37: 251 (April)
Simplified Nail Taping with Urea Ointment for Nonsurgical Nail Avulsion. *Averill/Scher*. 38: 231 (Oct)

EDITORIALS

Dermatology and New Jersey—A Good Match. *Schwartz*. 37: 16 (Jan)
Benefit of the Doubt. *Hardison*. 37: 150 (March)
Our Litigious Society. *Smith*. 37: 236 (April)
Organizations. *McCarthy*. 37: 318 (May)

Common and Uncommon. *McCarthy*. 37: 411 (June)
Caveat Emptor. *McCarthy*. 38: 16 (July)
Warts. *McCarthy*. 38: 87 (Aug)
Caveat Emptor: Part II. *McCarthy*. 38: 149 (Sept)
Who Is Taking Care of the Patients? *McCarthy*. 38: 222 (Oct)
A Great Friend. *McCarthy*. 38: 294 (Nov)
The Scholars. *McCarthy*. 38: 349 (Dec)

ENVIRONMENT VERSUS MAN

(Prepared especially for CUTIS by Joseph W. Burnett, MD, Gary J. Calton, PhD, and Robert J. Morgan, MD)
Centipedes. 37: 241 (April)
Caterpillar and Moth Dermatitis. 37: 320 (May)
Bedbugs. 38: 20 (July)
Venomous Stingray Injuries. 38: 112 (Aug)
Venomous Sea Urchins. 38: 151 (Sept)
Venomous Snakebites. 38: 299 (Nov)

FUNGUS DISEASES

(Prepared especially for CUTIS by Paul H. Jacobs, MD, FACP)
Fungal Infections of Human Hair. 37: 258 (April)
Majocchi's Granuloma (Due to Therapy with Steroid and Occlusion). 38: 23 (July)
Incidence of Dermatophyte Infection. 38: 90 (Aug)

LEARNING CLINICAL DERMATOLOGY THROUGH HISTOPATHOLOGY

(Prepared especially for CUTIS by A. Bernard Ackerman, MD, and Clay J. Cockerell, MD)
Cutaneous Lesions: Correlations from Microscopic to Gross Morphologic Features. 37: 137 (Feb)
Papules. 37: 242 (April)
Plaques. 37: 321 (May)
Nodules (and Tumors). 37: 414 (June)

MY MOST UNFORGETTABLE CASE

(Prepared especially for CUTIS by Ervin Epstein, Sr, MD)
Demodex folliculorum as a Pathogen. *Ayres*. 37: 441 (June)

CUTIS®

ADVERTISING REPRESENTATIVES

NEW YORK

Steven Claps—(212) 605-9629
Claudia A. Shayne—(212) 605-9798
875 Third Avenue, New York, NY 10022

BARRINGTON

Wyman Carey—(312) 381-1840
1301 S. Grove Avenue, Barrington, IL 60010

HOUSTON

Dick Sheehan—(713) 981-4090
9894 Bissonnet, Suite 100, Houston, TX 77036

ATLANTA

Robert H. Powell, Jr.—(404) 633-5112
4 Executive Drive, N.E., Atlanta, GA 30329

SAN FRANCISCO

Marjorie Hauschild—(415) 981-2594
582 Market Street, San Francisco, CA 94104

Production Manager: Mary Rando
Telephone: (212) 605-9475

Reprints Manager: Herbert V. Paureiss, Jr.
Telephone: (212) 605-9625
Telex 429073—Tech Pub

CAHNERS PUBLISHING COMPANY

875 Third Avenue, New York, NY 10022

William M. Platt
President, Magazine Division

Terrence M. McDermott
Executive Vice-President

Carroll V. Dowden
Group Vice-President

Saul Goldweitz
Chairman of the Board

Ronald Segel
President and Chief Executive Officer
Cahners Publishing Company

Jerry Neth
Vice-President, Publishing Operations

Jerry Walsh
Financial Vice-President, Magazine Division

Tom Dellamaria
Vice-President, Production and Manufacturing

ABP

BPA

Dermatitis Factitia. 38: 24 (July)
A Case of Silica Granuloma. *Morgan*. 38: 95 (Aug)
Pustular Psoriasis: From the Wheelchair to the Dance Floor. *Shelley/Shelley*. 38: 150 (Sept)
Nail Polish Dermatitis Masquerading as Atopic Dermatitis. *Fisher*. 38: 236 (Oct)
Sporotrichosis. *Brunsting*. 38: 302 (Nov)

PSORIASIS

(Prepared especially for CUTIS by
Eugene F. Farber, MD)
Application of Nuclear Magnetic Resonance Spectroscopy to Cutaneous Disease. *Kim et al.* 37: 20 (Jan)
New Strategies for Psoriasis Therapy. *Nickoloff*. 37: 421 (June)
Is the Dermal Fibroblast Significant in Psoriasis? *Cunningham et al.* 38: 93 (Aug)

SPECIAL FEATURES

Dermatology at the New Jersey Medical School (UMDNJ) and its Forerunner, the Seton Hall College of Medicine and Dentistry. *Schwartz*. 37: 34 (Jan)

THERAPEUTICS FOR THE CLINICIAN

A Controlled Two-Center Study of Lactate 12 Percent Lotion and a Petrolatum-Based Cream in Patients with Xerosis. *Wehr et al.* 37: 205 (March)
A Comparison of Clobetasol Propionate 0.05 Percent Ointment and an Optimized Betamethasone Dipropionate 0.05 Percent Ointment in the Treatment of Psoriasis. *Jacobson et al.* 37: 213 (March)
Efficacy of Alpha Keri After Showering for Treatment of Xerosis. *Wehr et al.* 37: 384 (May)
Treatment of Tinea Pedis with Econazole Nitrate Cream. *Cullen et al.* 37: 388 (May)
Terfenadine in Chronic Urticaria: A Comparison with Clemastine and Placebo. *Fredriksson et al.* 38: 128 (Aug)
A Comparison of Clindamycin Phosphate 1 Percent Topical Lotion and Placebo in the Treatment of Acne Vulgaris. *Kuhlman/Callen*. 38: 203 (Sept)
Topical Metronidazole in the Treatment of Rosacea. *Veien et al.* 38: 209 (Sept)

TROPICAL DERMATOLOGY

(Prepared especially for CUTIS by
Orlando Carizares, MD)
Yaws. *Nagreh*. 38: 303 (Nov)

